10-Q: Clene Inc. Q1 2026 Results: Focus on ALS, MS Drug Development

Clene Inc. reports Q1 2026 results, highlighting progress in ALS and MS drug development, while facing ongoing financial challenges and a going concern assessment.

Summary

• Clene Inc. reported its financial results for the first quarter ended March 31, 2026.
• The company incurred a net loss of $8.1 million, compared to a net loss of $0.75 million in the same period of 2025.
• Total revenue for the quarter was $15,000, a significant decrease from $81,000 in Q1 2025, primarily due to lower product and royalty revenue from 4Life.
• Research and development expenses decreased by 78% to $0.33 million, largely due to reduced spending on ALS clinical programs and cost-saving initiatives.
• General and administrative expenses also decreased by 34% to $1.75 million, attributed to lower legal fees, personnel costs, and stock-based compensation.
• The company's cash and cash equivalents stood at $5.9 million as of March 31, 2026.
• Clene Inc. continues to face substantial doubt about its ability to continue as a going concern, necessitating future financing.
• Significant progress was noted in the development of CNM-Au8 for ALS, with the FDA indicating that proposed data may support an NDA under an accelerated approval pathway.
• Discussions with the FDA regarding CNM-Au8 for Multiple Sclerosis are ongoing, with a focus on cognition as a potential primary endpoint.
• The company raised $6.0 million in gross proceeds from a registered direct offering in Q1 2026 and an additional $7.0 million subsequent to the quarter.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant increase in net loss, decrease in revenue, and the continued going concern warning, despite positive regulatory feedback on the ALS drug candidate.

Positives

• The FDA indicated that Clene's proposed data for CNM-Au8 may support an NDA submission for ALS under an accelerated approval pathway.
• The FDA noted that NfL could potentially serve as a reasonably likely surrogate endpoint for accelerated approval in ALS.
• The company plans to submit its NDA for ALS in the third quarter of 2026.
• The FDA expressed openness to considering cognition as a primary endpoint for CNM-Au8 in Multiple Sclerosis.
• The company successfully raised $6.0 million in gross proceeds from a registered direct offering in Q1 2026 and an additional $7.0 million subsequent to the quarter.
• Research and development expenses decreased by 78% to $0.33 million, and general and administrative expenses decreased by 34% to $1.75 million, reflecting cost-saving measures.
• The company has a patent-protected, proprietary position in clean-surfaced nanotechnology (CSN) therapeutics.

Negatives

• The company incurred a net loss of $8.1 million for the quarter, a significant increase from $0.75 million in the prior year.
• Total revenue decreased by 81% to $15,000.
• The company faces substantial doubt about its ability to continue as a going concern.
• The company has not generated significant revenue and does not anticipate doing so unless drug candidates are successfully developed and approved.
• The company's accumulated deficit was $316.4 million as of March 31, 2026.
• The company is heavily reliant on future financing to sustain operations.
• The fair value of common stock warrant liabilities increased by $7.0 million to $12.0 million, and derivative liabilities decreased by $0.7 million to $2.4 million.
• The company has identified material weaknesses in its internal control over financial reporting related to control environment, reconciliations, segregation of duties, and IT general controls.

Risks

• Substantial dependence on the successful commercialization of drug candidates, if approved.
• Significant net losses and net operating cash outflows.
• Inability to demonstrate the efficacy and safety of drug candidates.
• Clinical trial results may not support further development or marketing approval.
• Actions of regulatory agencies may affect the initiation, timing, and progress of clinical trials and marketing approval.
• Inability to achieve commercial success for drug candidates, if approved.
• Inability to obtain and maintain protection of intellectual property.
• Reliance on third parties to conduct research, drug development, and other services.
• Limited operating history and inability to obtain additional funding for operations and to complete the licensing or development and commercialization of drug candidates.
• The impact of any future epidemics, pandemics, or conflicts.
• Changes in applicable laws or regulations.
• The effects of inflation.
• The effects of staffing and materials shortages.
• The possibility of being adversely affected by other economic, business, and/or competitive factors.
• The company is required to maintain at least $2.0 million in unrestricted cash and cash equivalents to avoid acceleration of its 2024 SSCP Notes.
• The company has identified material weaknesses in internal control over financial reporting.

Future Outlook

The company expects to incur additional losses in the future as it advances its clinical-stage drug candidates. Future R&D expenses are expected to increase, particularly if assets move into Phase 3 trials or if an NDA is filed. G&A expenses are also expected to increase if an NDA is filed, supporting commercial capabilities. If an NDA is not approved, G&A expenses are expected to decrease due to cost-saving measures. The company anticipates needing additional financing within the next twelve months to sustain operations.

Management Comments

• The FDA stated that our proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway for the treatment of ALS.
• The FDA reminded the Company that the submission should demonstrate the effectiveness of an effect of CNM-Au8 on NfL and show that the magnitude of change in NfL is reasonably likely to predict clinical benefits in patients with ALS.
• The FDA has also requested that we provide additional information in our NDA, including to support a connection between the reported magnitude of reduction in NfL and clinical benefit, which we have prepared and will include in the submission.
• The FDA aligned with Clene acknowledging the limitations of the Expanded Disability Status Scale, a global measure of MS disease severity, and expressed openness to considering other potential primary endpoints, including cognition, to evaluate broader treatment effects.

Industry Context

StockSavvy.ai notes that Clene Inc.'s Q1 2026 report reflects the challenging financial landscape common to many clinical-stage biopharmaceutical companies, where significant R&D investment is required before potential revenue generation. The company's focus on ALS and MS aligns with a growing area of unmet medical need, and regulatory interactions with the FDA are critical milestones. The ongoing need for capital is a persistent theme in the sector, often addressed through equity offerings.

Comparison to Industry Standards

• Many clinical-stage biopharmaceutical companies, like Clene Inc., experience significant net losses and negative cash flows from operations for extended periods due to high R&D costs.
• The reliance on equity financing and debt to fund operations is a common strategy in the biotech sector, as seen with Clene's multiple equity offerings and notes payable.
• The process of seeking FDA approval for new drug applications (NDAs), particularly under accelerated pathways, is a standard but complex procedure in the pharmaceutical industry.
• The valuation of financial instruments such as stock warrants and derivatives is a common accounting challenge for companies with complex capital structures, as reflected in Clene's financial statements.
• The 'going concern' assessment is a frequent disclosure for companies in early-stage development that have not yet achieved profitability.

Legal Proceedings

• The company is not currently a party to any material pending legal proceedings.

Related Party Transactions

• The company has an Amended 4Life Agreements (Supply and License Agreements) with 4Life Research LLC, a stockholder, debt holder, and related party.
• Under the Supply Agreement, 4Life has an exclusive right to purchase certain dietary supplement and non-pharmaceutical products, with purchase price at cost plus 20%.
• Effective April 30, 2026, 4Life's exclusive rights to purchase and commercialize Licensed Products were converted to non-exclusive rights due to failure to meet Minimum Sales Commitment and pay additional royalty fees.
• Under the License Agreement, 4Life pays a royalty rate of 3% of incremental sales of Licensed Products.
• Total revenue from related parties (4Life) was $14,000 in Q1 2026, consisting of royalty revenue.
• The 2024 Senior Secured Convertible Promissory Notes were sold to related parties, including Kensington Clene 2024, LLC (controlled by an independent director), 4Life, and La Scala Investments, LLC (controlled by a stockholder and board member of a subsidiary).

Stakeholder Impact

• Shareholders: The increased net loss and going concern warning may negatively impact share price. Positive regulatory feedback on ALS drug offers potential upside.
• Creditors: The company's ability to meet its debt obligations is dependent on future financing, as indicated by the going concern assessment.
• Employees: Cost-saving initiatives, including potential staff reductions, may impact employees.
• Suppliers: The company's continued operations and ability to pay suppliers depend on securing additional financing.
• Customers: The dietary supplement business continues, but the primary focus is on drug development, which may impact the availability or focus on these products.

Next Steps

• Submit NDA for ALS in the third quarter of 2026.
• Continue discussions with regulatory authorities for MS indication.
• Advance CNM-Au8 into Phase 3 trials for MS.
• Continue to raise additional funding to sustain operations.
• Implement cost-saving initiatives.
• Remediate material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

Clene Inc. presents a high-risk, high-reward profile. The positive regulatory feedback for its ALS drug candidate (CNM-Au8) is a significant development, potentially paving the way for an NDA submission. However, the company's continued substantial net losses, negative cash flow, and the explicit 'going concern' warning necessitate caution. The significant increase in warrant liabilities and the ongoing need for capital are considerable headwinds. A 'hold' recommendation reflects the speculative nature of the investment, balancing the potential upside from drug approvals against the substantial financial and operational risks.

Keywords

Clene Inc., Form 10-Q, Quarterly Report, CNM-Au8, ALS, Multiple Sclerosis, Pharmaceutical, Clinical Stage, Drug Development, FDA, NDA, Accelerated Approval, Biotechnology, Neurodegenerative Diseases, Financial Results